Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBAYNASDAQ:GNPXNASDAQ:IFRXNASDAQ:MLNDNASDAQ:SAVA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.39$7.26▼$32.50$3.73B0.324.11 million shs73 shsGNPXGenprex$2.12-4.1%$3.46$2.09▼$42.40$4.05M-0.6171,465 shs8,586 shsIFRXInflaRx$1.39+2.2%$1.54$1.14▼$5.20$81.85M1.27237,628 shs146,063 shsMLNDMillendo Therapeutics$3.44+0.6%$4.00$0.92▼$16.95$65.51M0.481.52 million shs652,870 shsSAVACassava Sciences$21.73+4.8%$21.50$12.32▼$32.10$939.74M-0.45766,092 shs903,320 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%+44.61%+229.08%GNPXGenprex-4.33%0.00%-26.33%-75.75%-93.24%IFRXInflaRx0.00%+7.51%-11.69%-9.33%-71.06%MLNDMillendo Therapeutics+0.58%+2.69%-5.49%-5.75%+62.26%SAVACassava Sciences+0.92%-2.49%+5.28%-15.62%+32.58%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay Therapeutics0.9256 of 5 stars2.00.00.04.70.02.50.6GNPXGenprex4.2576 of 5 stars3.55.00.04.70.60.81.3IFRXInflaRx2.1831 of 5 stars3.83.00.00.00.01.71.3MLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.4782 of 5 stars3.51.00.04.71.70.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideGNPXGenprex3.00Buy$10.00371.70% UpsideIFRXInflaRx3.50Strong Buy$13.50871.22% UpsideMLNDMillendo TherapeuticsN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00470.64% UpsideCurrent Analyst RatingsLatest MLND, CBAY, IFRX, GNPX, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AIFRXInflaRx$63.09K1,297.33N/AN/A$1.89 per share0.74MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)GNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)IFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/ASAVACassava Sciences-$97.22M-$2.32N/A13.01N/AN/A-57.53%-52.58%5/6/2024 (Estimated)Latest MLND, CBAY, IFRX, GNPX, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 million2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96GNPXGenprexN/A2.312.31IFRXInflaRxN/A6.505.82MLNDMillendo TherapeuticsN/A6.396.39SAVACassava SciencesN/A9.139.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%GNPXGenprex14.05%IFRXInflaRx42.39%MLNDMillendo TherapeuticsN/ASAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%GNPXGenprex11.54%IFRXInflaRx16.30%MLNDMillendo TherapeuticsN/ASAVACassava Sciences12.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableGNPXGenprex261.91 million1.69 millionOptionableIFRXInflaRx6258.88 million49.29 millionOptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableMLND, CBAY, IFRX, GNPX, and SAVA HeadlinesSourceHeadlineCassava Sciences (NASDAQ:SAVA) Shares Down 6% americanbankingnews.com - April 21 at 5:34 AMHow Western food imports are fuelling obesity in Pacific nationsmsn.com - April 20 at 8:05 PMCassava Sciences, Inc. (SAVA)finance.yahoo.com - April 19 at 1:58 PMRail heralded as future for Thai logisticsbangkokpost.com - April 17 at 1:27 PMCassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher marketbeat.com - April 16 at 3:43 PMCassava Sciences (NASDAQ:SAVA) Sees Large Volume Increasemarketbeat.com - April 15 at 2:49 PMRedemption Date Announced for Warrantsglobenewswire.com - April 15 at 9:20 AMContrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)americanbankingnews.com - April 15 at 1:44 AMNicklaus: Path to world food security goes through St. Louisstltoday.com - April 14 at 7:17 AMCassava Sciences (NASDAQ:SAVA) Trading Down 9%marketbeat.com - April 12 at 2:51 PMVietnam has great potential for biofuel: expertsvietnamnet.vn - April 12 at 2:00 PMInvestors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA)marketbeat.com - April 11 at 4:50 PMCassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volumemarketbeat.com - April 9 at 3:19 PMFosukrom farmers trained on organic herbicides, pesticidesmodernghana.com - April 8 at 8:15 PMZambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Futureinsideclimatenews.org - April 8 at 8:15 PMCassava Sciences (NASDAQ:SAVA) Trading Up 5.7%marketbeat.com - April 8 at 1:46 PMGates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africaagfundernews.com - April 5 at 2:17 AM5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Revealsfood.ndtv.com - April 5 at 1:13 AMAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesbizjournals.com - April 5 at 1:13 AMStrong quake rocks Taiwan, tsunami warnings issuedmsn.com - April 4 at 4:16 PMCan Africa one day help feed the world’s growing population?ft.com - April 3 at 3:22 AMElevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacymyjoyonline.com - April 2 at 5:22 PM24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassavastockhouse.com - April 2 at 5:22 PMTracing science’s transformative impact on manifesto implementationmsn.com - April 2 at 10:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Millendo TherapeuticsNASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.